U.S., Oct. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07219563) titled 'Alnuctamab for Refractory SLE (LATTE Study)' on Oct. 20.
Brief Summary: This study will assess the safety and preliminary efficacy of the bi-specific TCE, alnuctamab (known as BMS-986349, CC-93269, EM901), targeting BCMA in patients with moderate to severe SLE, refractory to standard-of-care treatments.
Study Start Date: Dec. 01
Study Type: INTERVENTIONAL
Condition:
Systemic Lupus Erythematosus
Intervention:
DRUG: Alnuctamab
The study drug will be given as an injection under the skin. For the first 9 days after the CC-93269 injection, subjects will be staying in the hospital. The goal of this study is to determine the optimal...